Losmapimod一种是口服活性的p38 MAPK抑制剂,对p38α和p38β的pKi为8.1和7.6。
Losmapimod (GW856553) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
~12 mg/kg 口服
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Willette RN, et al. J Pharmacol Exp Ther. 2009, 330(3), 964-970.
分子式 C22H26FN3O2 |
分子量 383.46 |
CAS号 585543-15-3 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 72 mg/mL |
Water <1 mg/mL |
Ethanol 40 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT02000440 | Glomerulosclerosis, Focal Segmental | Drug: Losmapimod | GlaxoSmithKline | Phase 2 | 2014-07-01 | 2017-01-16 |
NCT02299375 | Pulmonary Disease, Chronic Obstructive | Drug: Losmapimod tablets|Drug: Placebo tablets | GlaxoSmithKline | Phase 2 | 2014-12-01 | 2017-01-16 |
NCT01756495 | Acute Coronary Syndrome | Drug: Losmapimod|Drug: Moxifloxacin|Drug: Losmapimod matched Placebo|Drug: Moxifloxacin Placebo | GlaxoSmithKline | Phase 1 | 2013-01-01 | 2017-01-27 |
NCT02145468 | Acute Coronary Syndrome | Drug: Losmapimod 7.5 mg twice daily|Drug: Placebo twice daily|Drug: Standard therapy | GlaxoSmithKline|The TIMI Study Group | Phase 3 | 2014-06-01 | 2017-03-21 |
NCT01541852 | Chronic Obstructive Pulmonary Disease | Drug: Losmapimod|Drug: Placebo | Cambridge University Hospitals NHS Foundation Trust|Technology Strategy Board, United Kingdom|GlaxoSmithKline|Royal Brompton & Harefield NHS Foundation Trust|University of Cambridge | Phase 2 | 2012-06-01 | 2015-03-15 |
NCT01648192 | Acute Coronary Syndrome | Drug: Losmapimod for single dose|Drug: Losmapimod for repeat dose | GlaxoSmithKline | Phase 1 | 2012-07-01 | 2017-01-31 |
NCT01218126 | Pulmonary Disease, Chronic Obstructive | Drug: losmapimod|Drug: placebo | GlaxoSmithKline | Phase 2 | 2010-11-01 | 2015-07-16 |
NCT00569062 | Depressive Disorder, Major | Drug: GW856553X|Other: Placebo | GlaxoSmithKline | Phase 2 | 2007-09-01 | 2015-06-08 |
NCT01039961 | Cardiovascular Disease | Drug: losmapimod 1 mg|Drug: losmapimod|Drug: losmapimod 15 mg | GlaxoSmithKline | Phase 1 | 2010-02-01 | 2017-01-27 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们